NMN raised NAD⁺, and kept biological age from rising

One of the cleanest looks at NMN in humans comes from a 60-day, randomised, double-blind, placebo-controlled trial across multiple centres. Eighty healthy middle-aged adults (average age ~49) were split evenly into four groups: placebo, or 300 mg, 600 mg, or 900 mg of NMN per day.

NAD⁺ went up, dose-dependently. Every NMN group raised blood NAD⁺ significantly versus placebo at both day 30 and day 60. The 600 mg and 900 mg groups reached the highest levels, with little extra benefit from going up to 900 mg, which is why 600 mg is often described as the practical sweet spot.

People moved better and felt better. Six-minute walking distance improved significantly in all NMN groups, again led by 600 mg and 900 mg. Self-reported quality of life (SF-36) was also significantly better than placebo by day 60.

Biological age held steady. Perhaps the most striking result: a blood-based biological-age measure rose in the placebo group over the two months, while the NMN groups held flat, a measurable gap between the two.

Safety. All 80 participants completed the study. Adverse events were few, mild, and actually more common in the placebo and 300 mg groups; the 600 mg and 900 mg groups reported none.

This is the kind of evidence behind Rejuvi: a meaningful daily dose of pure NMN to support NAD⁺, the molecule your cells use for energy and repair.

This summary is for education only and is not medical advice. Individual results vary. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease.